Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial

IMPORTANCE: Randomized clinical trials have demonstrated a substantial benefit of adding everolimus to endocrine therapy. Everolimus inhibits the mammalian target of rapamycin complex 1 (mTORC1) complex but not mTORC2, which can set off an activating feedback loop via mTORC2. Vistusertib, a dual inh...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:JAMA Oncol
Egile Nagusiak: Schmid, Peter, Zaiss, Matthias, Harper-Wynne, Catherine, Ferreira, Marta, Dubey, Sidharth, Chan, Stephen, Makris, Andreas, Nemsadze, Gia, Brunt, Adrian M., Kuemmel, Sherko, Ruiz, Isabel, Perelló, Antonia, Kendall, Anne, Brown, Janet, Kristeleit, Hartmut, Conibear, John, Saura, Cristina, Grenier, Julien, Máhr, Károly, Schenker, Michael, Sohn, Joohyuk, Lee, Keun Seok, Shepherd, Christopher J., Oelmann, Elisabeth, Sarker, Shah-Jalal, Prendergast, Aaron, Marosics, Patricia, Moosa, Atiyyah, Lawrence, Cheryl, Coetzee, Carike, Mousa, Kelly, Cortés, Javier
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Medical Association 2019
Gaiak:
Original Investigation
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6865233/
https://ncbi.nlm.nih.gov/pubmed/31465093
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.2526
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak